Here are the Form 4 insider transactions from CRISPR Therapeutics AG (CRSP) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CRSP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRSP filings page.
CRISPR Therapeutics AG Chief Financial Officer Andrew Jacob Silver was granted an option covering 18,000 Common Shares on October 26, 2026, with a $49.01 per-share exercise price. The option vests in 48 equal monthly installments beginning November 26, 2026. Silver also received 9,000 restricted stock units on October 26, 2026; each represents a contingent right to receive one Common Share, with one quarter vesting on each October 26 from 2027 through 2030.
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger received two equity awards on October 26, 2026: a stock option covering 18,000 Common Shares with a $49.01 exercise price, and 9,000 Restricted Stock Units, each a contingent right to receive one Common Share. The option vests in 48 equal monthly installments starting November 26, 2026, and expires October 26, 2036. One quarter of the restricted stock units vests on each of October 26, 2027, 2028, 2029, and 2030.
CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni was granted a stock option covering 57,500 Common Shares and restricted stock units covering 28,750 Common Shares on October 26, 2026. The option has an exercise price of $49.01 per share, vests in 48 equal monthly installments beginning November 26, 2026, and expires October 26, 2036. Each restricted stock unit represents a contingent right to receive one Common Share; one quarter vests on each of October 26, 2027, 2028, 2029, and 2030.
CRISPR Therapeutics AG reported that its Chief Medical Officer, Naimish Patel, was granted options covering 24,000 Common Shares and 12,000 restricted stock units on October 26, 2026. The options have a $49.01 per-share exercise price and vest in 48 equal monthly installments beginning November 26, 2026. The restricted stock units vest in four annual installments of one quarter each, from October 26, 2027, through October 26, 2030.
CRISPR Therapeutics AG Chief Financial Officer Andrew Jacob Silver received a grant of 25,000 restricted stock units on October 19, 2026. The award provides for 100% of the shares to vest on October 19, 2028. This was a grant/award acquisition, rather than a purchase or sale.
CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni converted 100,000 restricted stock units into 100,000 Common Shares on October 16, 2026, with 200,000 restricted stock units reported afterward. On October 19, he sold 47,837 Common Shares at $49.78 per share; the sale was required under the company's RSU Settlement Policy to fund tax withholding from vesting and was not discretionary.
CRISPR Therapeutics AG director Simeon George exercised an option for 30,000 Common Shares at an exercise price of $14.0000 per share on October 14, 2026, and sold 14,514 Common Shares that day at a weighted-average price of $49.6330 per share. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2025.
Indirect holdings listed were 69,687 Common Shares held by SR One Fund II Aggregator, 238,897 held by SR One Opportunities Fund I, and 1,730,179 held by AMZL. George disclaims beneficial ownership of portions held by those entities in which he has no pecuniary interest.
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported that 2,113 restricted stock units vested on October 13, 2026, resulting in 2,113 common shares. He sold 1,040 common shares on October 14, 2026, at $49.26 per share. The sale was required under the company’s RSU Settlement Policy to fund tax withholding and was not discretionary; no Rule 10b5-1 plan is reported.
CRISPR Therapeutics AG (CRSP) Chief Executive Officer Samarth Kulkarni received 8,333 Common Shares on October 13, 2026, when 8,333 restricted stock units vested. On October 14, 2026, he sold 4,098 Common Shares at $49.26 per share. The sale was required under the company's RSU Settlement Policy to fund tax withholding and was not a discretionary trade.
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger exercised options for 1,990 common shares on October 6, 2026, at a $13.62 exercise price, and sold 1,990 shares at a weighted average of $60.0408 per share. Sale prices ranged from $60.00 to $60.08, inclusive. His reported stock-option position after the transaction was 81,242 shares. The sales were made under a Rule 10b5-1 trading plan adopted May 6, 2026.
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger exercised options covering 10,400 common shares on September 22, 2026, at an exercise price of $13.62 per share, acquired 10,400 shares, and sold 10,400 shares at a weighted average price of $60.2365 per share. The sales were made under a Rule 10b5-1 trading plan adopted May 6, 2026. The option transaction reported 83,232 shares following the exercise.
CRISPR Therapeutics AG (CRSP) director Ali Behbahani exercised stock options for 30,000 Common Shares at $14.00 per share on September 17, 2026, and received 30,000 Common Shares. On the same date, he sold 13,679 Common Shares at a weighted average price of $57.0901 per share in multiple transactions at prices ranging from $56.97 to $57.43 per share. The exercised options were originally granted on October 18, 2016, vesting in 36 equal monthly installments beginning October 31, 2016. Following these transactions, an entity associated with him, The Ali Behbahani Revocable Trust Dated June 26, 2015, is reported as the direct beneficial owner of 29 Common Shares, with Behbahani as trustee and disclaiming beneficial ownership of any portion in which he has no pecuniary interest. No Rule 10b5-1 trading plan is reported for these transactions.
CRISPR Therapeutics AG (symbol: CRSP) is the issuer of record for a Form 4 filing submitted to the SEC. Behbahani Ali reported acquisition or exercise transactions in this Form 4 filing.
CRISPR Therapeutics AG (CRSP) director Ali Behbahani reported receiving Common Shares through an entity restructuring transaction on August 6, 2025. A pro rata distribution by NEA Partners 15, L.P. transferred 60 Common Shares to him directly, bringing his directly held position to 316 Common Shares.
The same distribution transferred 15 Common Shares to The Ali Behbahani Revocable Trust Dated June 26, 2015, resulting in 29 Common Shares held indirectly. He serves as trustee of the trust and disclaims beneficial ownership of any trust shares in which he has no pecuniary interest. No Rule 10b5-1 trading plan is reported.
CRISPR Therapeutics AG Chief Financial Officer Prasad Raju reported a bona fide gift of 750 Common Shares on 2026-08-07. The transfer is classified as a disposition, and following the gift he reports 14,815 Common Shares held directly.
CRISPR Therapeutics AG director George Simeon received a grant of stock options for 13,000 common shares. The options carry an exercise price of $51.84 per share and expire on June 5, 2036. This is a compensation-related award, not an open-market trade.
According to the vesting terms, the options vest in 12 equal monthly installments, subject to his continued service. The first installment vests on June 30, 2026, and the final installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting.
CRISPR Therapeutics AG director Ali Behbahani received a new stock option grant covering 13,000 common shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036. They were awarded as compensation rather than bought on the open market.
According to the vesting terms, the options vest in 12 equal monthly installments, with the first installment on June 30, 2026. The final installment vests on the earlier of the one-year anniversary of the grant date or the date of the company’s 2027 annual meeting.
CRISPR Therapeutics AG director Maria Fardis received a grant of stock options, giving her the right to buy 13,000 common shares at an exercise price of $51.84 per share. These options were awarded as compensation, not through open-market buying or selling.
According to the vesting terms, the 13,000 options will vest in 12 equal monthly installments, with the first installment vesting on June 30, 2026. The final installment will vest on the earlier of the one-year anniversary of the grant date or the date of the company’s 2027 Annual Meeting, assuming she continues to provide service to the company or its subsidiaries.
CRISPR Therapeutics AG reported that director Harold Edward Fleming received a grant of stock options covering 13,000 common shares. The options have an exercise price of 51.84 per share and expire on June 5, 2036. Subject to continued service, they vest in 12 equal monthly installments, beginning with the first installment on June 30, 2026 and the last on the earlier of the one-year anniversary of the grant date or the 2027 annual meeting.
CRISPR Therapeutics AG director John Greene received a grant of stock options covering 13,000 common shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036.
According to the vesting terms, the award vests in 12 equal monthly installments, subject to continued service. The first installment vests on June 30, 2026, and the last installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting.
CRISPR Therapeutics AG director Katherine A. High received a grant of 13,000 stock options on Common Shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036. They vest in 12 equal monthly installments, beginning June 30, 2026, subject to continued service, with final vesting on the earlier of the one-year anniversary of grant or the 2027 Annual Meeting.
CRISPR Therapeutics AG reported that director Sandesh Mahatme received a grant of stock options covering 13,000 common shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036.
According to the terms, the award vests in 12 equal monthly installments, subject to continued service, with the first installment vesting on June 30, 2026. The final installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting. This is a compensation-related award rather than an open-market purchase or sale.
CRISPR Therapeutics AG director Morrison Briggs received a grant of stock options for 13,000 common shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036.
According to the vesting terms, the options vest in 12 equal monthly installments, subject to continued service. The first installment vests on June 30, 2026, and the final installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting.
CRISPR Therapeutics AG director Christian Rommel received a grant of stock options for 13,000 common shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036. This is a compensation-related award, not an open-market purchase or sale.
According to the vesting terms, the options will vest and become exercisable in 12 equal monthly installments, with the first installment vesting on June 30, 2026. The final installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting, subject to his continued service.
CRISPR Therapeutics AG director Douglas A. Treco received a stock option grant covering 13,000 common shares. The option has an exercise price of $51.84 per share and was awarded at no purchase cost to him on the grant date.
The option expires on June 5, 2036. According to the vesting terms, it becomes exercisable in 12 equal monthly installments, with the first vesting on June 30, 2026 and the final installment vesting on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting.
KASINGER JAMES R. reported acquisition or exercise transactions in this Form 4 filing.
CRISPR Therapeutics AG reported that its General Counsel and Secretary, James R. Kasinger, received a grant of 17,000 restricted stock units. Each unit represents a right to receive one common share. All 17,000 units are scheduled to vest on November 29, 2028, if the vesting conditions are met.
Patel Naimish reported acquisition or exercise transactions in this Form 4 filing.
CRISPR Therapeutics AG reported that Chief Medical Officer Naimish Patel received a grant of 22,000 restricted stock units. Each unit represents one common share. The award was granted as compensation on May 29, 2026, and all 22,000 units are scheduled to vest on November 29, 2028, subject to the usual conditions.
Prasad Raju reported acquisition or exercise transactions in this Form 4 filing.
CRISPR Therapeutics AG reported that its Chief Financial Officer, Prasad Raju, received a grant of 19,500 Restricted Stock Units on May 29, 2026. Each RSU represents a contingent right to receive one common share, so this award ties directly to future share ownership.
All 19,500 underlying common shares will vest in a single tranche on November 29, 2028, aligning the CFO’s compensation with the company’s long-term performance. Following this grant, the filing shows 19,500 derivative securities linked to common shares held directly.
CRISPR Therapeutics AG Chief Medical Officer Naimish Patel reported RSU vesting and a related share sale. On May 28, 10,000 Restricted Stock Units converted into 10,000 Common Shares at $0.00 per share. On May 29, 3,786 Common Shares were sold at $55.62 per share to cover tax withholding, as mandated by the company’s RSU Settlement Policy and described as non-discretionary. Following these transactions, Patel directly held 19,357 Common Shares. The underlying RSU award covers 40,000 shares, with 10,000-share tranches scheduled to vest annually from 2025 through 2028.
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported a mix of equity grants, vesting, and a small share sale tied to taxes. He received a stock option for 38,499 Common Shares at an exercise price of $46.24 per share, vesting in 48 equal monthly installments starting on April 20, 2026. He was also granted 25,000 Restricted Stock Units (RSUs) that will vest in four annual installments of 6,250 shares each from March 20, 2027 through March 20, 2030.
On March 20, 2026, 6,250 RSUs from a prior 2024 grant vested and were converted into 6,250 Common Shares. On March 23, 2026, 3,182 Common Shares were sold at $46.78 per share to cover tax withholding obligations under the company’s RSU Settlement Policy, which the footnote states was not a discretionary trade. After these transactions, Kasinger directly held 94,308 Common Shares, which remain subject to a lock-up agreement related to the company’s offering of convertible senior notes due 2031.
CRISPR Therapeutics CEO Samarth Kulkarni reported a mix of equity grants, vesting, and a small mandated share sale. On March 20, 2026, restricted stock units covering 19,687 Common Shares vested and were settled into shares, and he received a new stock option for 114,249 Common Shares at an exercise price of $46.24, plus a new restricted stock unit award for 81,875 Common Shares with vesting from 2027 through 2030.
On March 23, 2026, 10,020 Common Shares were sold at $46.78 per share solely to cover tax withholding tied to the RSU vesting, pursuant to the company’s RSU Settlement Policy and described as a non-discretionary transaction. After these events, Kulkarni held 255,501 Common Shares directly, and certain shares remain subject to a lock-up agreement related to the company’s convertible senior notes due 2031.
CRISPR Therapeutics AG Chief Financial Officer Prasad Raju reported a mix of equity awards, an option exercise, and a mandated share sale. On March 20, 2026, he received a stock option covering 38,499 Common Shares at an exercise price of $46.24 per share, vesting in 48 equal monthly installments starting April 20, 2026. He was also granted 27,500 restricted stock units (RSUs), scheduled to vest in four annual tranches from March 20, 2027 through March 20, 2030.
On the same date, 6,250 RSUs from a prior 2024 award vested and were converted into 6,250 Common Shares. On March 23, 2026, Raju sold 3,708 Common Shares at an average price of $46.78 per share. A footnote states this sale was required to cover tax withholding on the RSU vesting under the company’s RSU Settlement Policy and "does not represent a discretionary trade". After these transactions, he directly held 15,565 Common Shares, which remain subject to a lock-up agreement related to the issuer’s convertible senior notes due 2031.
CRISPR Therapeutics AG granted equity awards to its Chief Medical Officer, Naimish Patel. On March 20, 2026, he received stock options covering 38,499 common shares at an exercise price of $46.24 per share, vesting in 48 equal monthly installments starting April 20, 2026.
He was also awarded 30,000 restricted stock units, each representing one common share. These RSUs vest in four equal annual installments on March 20 of 2027, 2028, 2029 and 2030. Both awards are recorded as direct ownership and reflect compensation-related acquisitions rather than open-market purchases.
CRISPR Therapeutics AG Chief Medical Officer Naimish Patel reported routine equity compensation activity, including RSU vesting and a mandated tax-related sale. On March 14, 2026, 8,125 Restricted Stock Units converted into 8,125 Common Shares at $0.00 per share, representing the first quarter of a 32,500-share RSU grant awarded on March 14, 2025.
A separate footnote explains that 3,150 Common Shares were sold at $48.26 per share on March 16, 2026 solely to cover tax withholding obligations tied to this vesting, as required by the company’s RSU Settlement Policy, and that this did not represent a discretionary trade. Following these transactions, Patel directly owns 13,143 Common Shares, including 592 acquired under the 2016 Employee Stock Purchase Plan, and holds 24,375 unvested Restricted Stock Units that continue to vest annually through March 14, 2029.
CRISPR Therapeutics AG Chief Financial Officer Prasad Raju exercised and vested restricted stock units and related common shares, then disposed of a portion mainly for tax obligations and a gift. On March 14, 2026, he acquired 16,875 common shares through the conversion of restricted stock units granted in 2023 and 2025. On March 16, 2026, 9,869 common shares were sold at $48.26 per share to satisfy tax withholding requirements under the company’s RSU Settlement Policy, and 750 shares were transferred as a bona fide gift without consideration. After these transactions, he directly held 13,023 common shares, which remain subject to a lock-up related to the company’s convertible senior notes due 2031.
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported RSU vesting and a related share sale. On March 14, 2026, 6,875 restricted stock units converted into 6,875 common shares at $0.00 per share, as part of a 27,500-share RSU grant vesting annually from 2026 to 2029.
On March 16, 2026, he sold 3,450 common shares at $48.26 per share to cover tax withholding obligations under the company’s RSU Settlement Policy, which the footnote states was not a discretionary trade. After these transactions, he directly holds 91,240 common shares and 20,625 restricted stock units, with remaining shares subject to a lock-up agreement tied to the company’s convertible senior notes due 2031.
CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni reported RSU vesting and a related tax sale. On March 14, 2026, 20,625 Restricted Stock Units vested and were converted into 20,625 Common Shares at a conversion price of $0.00 per share.
The vested RSUs are part of an 82,500-share award granted on March 14, 2025, scheduled to vest in four equal annual installments through March 14, 2029. On March 16, 2026, 10,349 Common Shares were sold at $48.26 per share to cover tax withholding obligations under the company’s RSU Settlement Policy, which the footnotes state does not represent a discretionary trade. After these transactions, Kulkarni directly holds 245,834 Common Shares and 61,875 Restricted Stock Units.
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported an RSU vesting and related share sale. On March 10, 2026, he acquired 5,500 Common Shares at $0.00 per share through the exercise of Restricted Stock Units, reflecting part of a 22,000-share award granted on March 10, 2023.
On March 11, 2026, he sold 2,800 Common Shares at an average price of $52.80 per share. A footnote states these shares were sold to cover tax withholding obligations under the company’s RSU Settlement Policy and were not a discretionary trade. After these transactions, he directly owned 87,815 Common Shares.
CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni reported compensation-related share activity. On March 10, 2026, 19,250 restricted stock units were exercised into 19,250 Common Shares at $0.00 per share, reflecting vesting of part of a prior equity award.
On March 11, 2026, 9,798 Common Shares were sold at $52.80 per share. A footnote explains this amount was required to be sold to cover tax withholding tied to the RSU vesting under the company’s RSU Settlement Policy, and therefore did not represent a discretionary trade. After these transactions, Kulkarni directly held 235,558 Common Shares.
CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni reported RSU vesting and a related share sale. On February 18, 2026, he acquired 13,250 Common Shares at $0.00 per share through the exercise/settlement of restricted stock units.
On February 19, 2026, he sold 6,967 Common Shares at an average price of $52.58 per share. A footnote explains that this sale was required to cover tax withholding obligations under the company’s RSU Settlement Policy and was not a discretionary trade. After these transactions, he directly held 226,106 Common Shares.
The restricted stock units were originally granted on February 18, 2022 for 53,000 Common Shares, vesting in four equal annual installments through February 18, 2026.
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported a mix of equity transactions involving company stock. On February 18, 2026, he acquired 3,825 Common Shares through the exercise and settlement of restricted stock units at a price of $0.00 per share, increasing his direct holdings to 87,227 Common Shares. On February 19, 2026, 2,112 Common Shares were sold at an average price of $52.58 per share to cover tax withholding obligations related to the RSU vesting, as required by the company’s RSU Settlement Policy and not as a discretionary trade. After these transactions, he directly owned 85,115 Common Shares.
CRISPR Therapeutics’ Chief Medical Officer, Naimish Patel, reported buying 1,508 common shares at $32.96 each on April 3, 2025. This direct ownership transaction brought his total reported holdings to 1,508 shares.
The filing notes this purchase was matchable under Section 16(b) with a later sale of 1,508 shares at $35.94 per share on May 29, 2025 under a mandatory “sell to cover” for a vested restricted stock unit. Patel agreed to pay CRISPR Therapeutics $4,493.84, equal to the full short-swing profit.
CRISPR Therapeutics’ Chief Financial Officer Prasad Raju reported an option exercise and share sale. On January 22, 2026, he exercised a stock option for 34,972 Common Shares at an exercise price of $45.15 per share, acquiring the same number of common shares. That same day, he sold 34,972 Common Shares at a weighted average price of $60.19 per share under a pre-arranged Rule 10b5-1 trading plan adopted on August 18, 2025. After these transactions, he directly held 6,767 Common Shares and 41,667 stock options.
CRISPR Therapeutics Chief Executive Officer and director Samarth Kulkarni reported multiple open-market sales of common shares under a pre-set Rule 10b5-1 trading plan adopted on August 27, 2025. On January 20, 2026, he sold 21,433 common shares at a weighted average price of $51.61 and 8,567 common shares at a weighted average price of $52.10. On January 22, 2026, he sold 60,000 common shares at a weighted average price of $60.23. Following these transactions, Kulkarni beneficially owns 134,201 common shares directly and 85,622 common shares indirectly through The Kulkarni 2023 GRAT.
CRISPR Therapeutics AG Chief Financial Officer Prasad Raju exercised stock options for 29,700 Common Shares on January 6, 2026 at exercise prices of $45.15 and $44.31 per share, then sold 29,700 Common Shares at weighted average prices of $60.1799, $60.0000 and $60.2134 per share under a Rule 10b5-1 trading plan adopted on August 18, 2025. Following these transactions, he directly holds 84,132 stock options and 6,767 Common Shares.
CRISPR Therapeutics AG’s Chief Financial Officer, who files individually, reported automatic sales of company stock. On December 22, 2025, the officer sold a total of 10,000 common shares of CRISPR Therapeutics AG in three separate transactions, at weighted average prices of $55.1022, $56.3345, and $56.8858 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 18, 2025, which is designed to provide an affirmative defense for insiders trading under predetermined instructions. After these sales, the officer beneficially owns 6,767 common shares directly.